Research Services
(SNMX) Senomyx Leads ValuEngine.com Forecast Screen
Flavoring manufacturer Senomyx uses proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into flavoring manufacturer product discovery and development collaborations...
(CVD) Big Pharmaceutical Companies Outsourcing Research and Development
by Tony D’Altorio, Investment U Research
Thursday, October 14, 2010
Big...
(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test
Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed...
(GPRO) Gen-Probe’s Earnings Report Leaps Ahead of Forecast
Diagnostic product maker Gen-Probe Inc. (GPRO) announced second-quarter fiscal 2010 adjusted earnings of 52 cents per share, exceeding the Zacks Consensus Estimate of 49 cents and the year-ago earnings of...
(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences
Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing...
(GTF) Cytomedix Analyst Awards Outperform Rating
We are initiating coverage of Cytomedix (GTF) with an ‘Outperform’ rating and near-term price target of $1.50 per share. At this price, we do not believe the market has come to grips with the transformation...
(OXBT) Oxygen Biotherapeutics Moves Into New Business
This morning, Oxygen Biotherapeutics (OXBT) announced that the company has begun distribution for its new formulation of Dermacyte (perfluorocarbon oxygen concentrated gel) for the beauty and skin care market....
(RX) IMS Health Reports Earnings In Line
IMS Health (RX) reported fourth-quarter earnings per share (EPS) of 39 cents, in line with the Zacks Consensus Estimate. However, after adjusting for charges related to restructuring initiatives, asset impairment...
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a...
(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval
Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned...
(RX) IMS Health to be Acquired by Funds Managed by TPG Capital
IMS Health (RX) recently agreed to its acquisition by investment funds managed by TPG Capital (TPG) and the Canada Pension Plan Investment Board (CPPIB) for a total value of $5.2 billion.
The Board of...
(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance...
(RX) IMS Health Earnings Ahead of Consensus Estimates
This morning, IMS Health (RX) reported third-quarter earnings per share of 40 cents, beating the Zacks Consensus Estimate by 4 cents. However, earnings declined 7% from the year-ago period. Revenues came in at $540.8 million. With clients reining in their...
(PRXL) PAREXEL International Corporation – Value – Zacks Rank Buy
PAREXEL International Corporation (PRXL), which provides consulting services to the drug and medical device industries, reported record service revenue that climbed 15.6% in its fiscal second quarter. The company has surprised on estimates 4 consecutive quarters...
(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents
Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.
(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents
Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.
(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents
Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.
(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents
Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.
(AMRI) – Albany Molecular Research – A 140% Earnings Surprise
Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.
Company Description
Albany...
(AMRI) – Albany Molecular Research – A 140% Earnings Surprise
Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.
Company Description
Albany...
(AMRI) – Albany Molecular Research – A 140% Earnings Surprise
Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.
Company Description
Albany...
(AMRI) – Albany Molecular Research – A 140% Earnings Surprise
Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.
Company Description
Albany...
(ICLR) – ICON Plc – Analysts project an earnings growth rate of 32%
ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.
Company Description
ICON Plc....
(ICLR) – ICON Plc – Analysts project an earnings growth rate of 32%
ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.
Company Description
ICON Plc....
(ICLR) – ICON Plc – an indication that investors are expecting strong earnings from the company
ICON Plc’s (ICLR) share price has been steadily climbing higher for most of 2008, producing excellent returns in a very challenging environment. The company’s second-quarter results were ahead of analyst estimates for the fourth time in the last four quarters,...